ContractLicense Agreement • May 4th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • New York
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
LICENSE AGREEMENTLicense Agreement • May 4th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS LICENSE AGREEMENT (this “Agreement”) is made effective as of the 13 day of August, 2014 (the “Effective Date”), by and between bluebird bio, Inc., a Delaware corporation having its principal place of business at 150 Second Street, Third Floor, Cambridge, MA 02141 (“Bluebird”), and Biogen Idec MA Inc., a Massachusetts corporation having its principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”). Bluebird and Biogen may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
Via Hand Delivery - Personal and ConfidentialLetter Agreement • May 4th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter agreement (the “Agreement”) confirms that your employment with bluebird bio, Inc. (“bluebird” or the “Company”) will be terminating without Cause under Section 3(d) of your Employment Agreement with the Company dated October 20, 2014 (the “Employment Agreement”). You agree that this Agreement is valid notice under Section 15 of your Employment Agreement. This Agreement establishes an amicable arrangement under which you release the Company from any claims, and, in return, you receive severance pay and medical and dental continuation benefits as provided in Section 4(b) of the Employment Agreement.
Amendment No. 1Master Collaboration Agreement • May 4th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amended and Restated Master Collaboration Agreement (this “Amendment No. 1”) is made as of February 17, 2016 (“Amendment No. 1 Effective Date”), by and between bluebird bio, Inc. (“Bluebird”), a Delaware corporation, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), and Celgene European Investment Company LLC (“Celgene Europe”), a Delaware limited liability company (Celgene Europe and Celgene Corp., together, “Celgene”). Each of Bluebird and Celgene may be referred to herein as a “Party” or together as the “Parties”. Reference is hereby made to that certain Amended and Restated Master Collaboration Agreement, by and between Bluebird, Celgene Corp. and Celgene Europe, dated June 3, 2015 (the “Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
PATENT LICENSE AGREEMENT – EXCLUSIVEPatent License Agreement • May 4th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 4th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This is an Amendment dated March 7, 2016 (the “Amendment”) to the Employment Agreement between bluebird bio, Inc., a Delaware corporation (the “Company”), and Jason F. Cole (the “Executive”) dated February 3, 2014 (the “Employment Agreement”).
